Announcing Research 101 | UMR Answers Common Questions About NIH Research in this New Fact Sheet Series
Read UMR's Dec. 8 Letter to Congressional Leadership on the Urgent Need to Pass an FY23 Omnibus Appropriations Bill
Why Invest in NIH Research? | UMR Offers Fact Sheets Explaining Why Congress Must #keepNIHstrong
NIH's Role In Sustaining the U.S. Economy | 2022 Update Now Available

A participant in the NIH 2019-2020 Medical Research Scholars Program.

Photo Credit: National Institutes of Health

About This Photo

What the Latest Johnson & Johnson COVID-19 Vaccine Trial Data Really Means [VIDEO]

What the Latest Johnson & Johnson COVID-19 Vaccine Trial Data Really Means [VIDEO]

Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels, Harvard’s Dr. Dan Barouch and others discuss where we are in the fight against COVID-19 and learn what’s next for vaccine development. Plus, other news with Dr. Uché Blackstock.

Dr. Fauci explained the advantages J&J’s one-shot coronavirus vaccine has over other drugs

Johnson & Johnson announced on Friday the results of its coronavirus vaccine Phase 3 trial, revealing to the world that the drug can prevent severe COVID-19 that leads to hospitalization and death. The vaccine is safe to use and had no serious side-effects during the massive Phase 3 trial. The company also said that the … Continued

Johnson & Johnson vaccine shows high efficacy against severe COVID-19 cases [VIDEO]

In an interview with ABC News, Dr. Dan Barouch, a researcher who helped develop the Johnson & Johnson vaccine, breaks down the vaccine’s efficacy and how new variants complicated its development.

J&J’s one-shot Covid vaccine is safe and generates promising immune response in early trial

Johnson & Johnson’s one-dose coronavirus vaccine is safe and appears to generate a promising immune response in both young and elderly volunteers, according to trial data published Wednesday in the New England Journal of Medicine. J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a … Continued

Have Questions About Participating in a COVID-19 Vaccine Clinical Trial? A Doctor Overseeing a Study Helps Answer Them

Njira Lugogo, M.D., is a pulmonologist who is leading a clinical study of an investigational COVID-19 vaccine candidate. She helps answer common questions people may have about the process, from what people over 60 need to know to how participants are being kept safe during the pandemic.

Video: How 3 Brilliant Women Are Changing the Game When It Comes to COVID-19

Lisa Ling speaks to Dr. Uché Blackstock about the racial inequities the pandemic has exposed, Dr. Alison Schwartz about battling a COVID-19 spike in Wisconsin and 14-year-old Anika Chebrolu about her prize-winning potential coronavirus therapy.

Video: Stanford COVID-19 Vaccine Trial Enters Phase Three

New video shows the first injection as Stanford doctors start phase three of the Johnson and Johnson COVID-19 vaccine trial. This phase three trial will be done at 180 sites around the world with 60,000 participants, 1,000 of them at Stanford. It’s a double-blind study, meaning some will get active vaccine while others will get … Continued

Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a vaccine is available

Pfizer Inc and Johnson & Johnson are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo. Both U.S. companies are among a handful with pivotal, late-stage COVID-19 vaccine trials underway. The … Continued

The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works

Johnson & Johnson just announced the launch of a Phase 3 clinical trial for its COVID-19 vaccine candidate. But what does this step in the process really mean? We asked two experts whose job it is to test vaccines to help demystify the clinical trial process—step by step.

NIH tests therapies to help cut hospital stays for COVID-19 patients

The U.S. National Institutes of Health (NIH) has started a late-stage trial to evaluate if immune-modulating therapies from three drugmakers can help reduce the need for ventilators for COVID-19 patients and shorten their hospital stay. The NIH said on Friday it has selected three agents for the study – Johnson & Johnson, Janssen Research’s Remicade, … Continued